ES2544808T3 - Miméticos sintéticos de LTA y uso de los mismos como componente de vacuna para la terapia y/o profilaxis de infecciones gram-positivas - Google Patents

Miméticos sintéticos de LTA y uso de los mismos como componente de vacuna para la terapia y/o profilaxis de infecciones gram-positivas Download PDF

Info

Publication number
ES2544808T3
ES2544808T3 ES11157947.0T ES11157947T ES2544808T3 ES 2544808 T3 ES2544808 T3 ES 2544808T3 ES 11157947 T ES11157947 T ES 11157947T ES 2544808 T3 ES2544808 T3 ES 2544808T3
Authority
ES
Spain
Prior art keywords
lta
prophylaxis
gram
therapy
vaccine component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11157947.0T
Other languages
English (en)
Spanish (es)
Inventor
Johannes Huebner
Andrea Kropec-Huebner
Gijsbert Arie Van Der Marel
Wouter Frederik Johan HOGENDORF
Jeroen Dirk Cornelis CODÉE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaetsklinikum Freiburg
Universiteit Leiden
Original Assignee
Universitaetsklinikum Freiburg
Universiteit Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaetsklinikum Freiburg, Universiteit Leiden filed Critical Universitaetsklinikum Freiburg
Application granted granted Critical
Publication of ES2544808T3 publication Critical patent/ES2544808T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/11—Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES11157947.0T 2011-03-11 2011-03-11 Miméticos sintéticos de LTA y uso de los mismos como componente de vacuna para la terapia y/o profilaxis de infecciones gram-positivas Active ES2544808T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20110157947 EP2500349B1 (en) 2011-03-11 2011-03-11 Synthetic LTA mimetics and use thereof as vaccine component for therapy and/or prophylaxis against gram-positive infections

Publications (1)

Publication Number Publication Date
ES2544808T3 true ES2544808T3 (es) 2015-09-04

Family

ID=43828266

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11157947.0T Active ES2544808T3 (es) 2011-03-11 2011-03-11 Miméticos sintéticos de LTA y uso de los mismos como componente de vacuna para la terapia y/o profilaxis de infecciones gram-positivas

Country Status (6)

Country Link
US (1) US9290531B2 (OSRAM)
EP (1) EP2500349B1 (OSRAM)
JP (1) JP6154751B2 (OSRAM)
CA (1) CA2829126A1 (OSRAM)
ES (1) ES2544808T3 (OSRAM)
WO (1) WO2012119846A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10364298B2 (en) 2011-11-18 2019-07-30 National Research Council Of Canada Clostridium difficile lipoteichoic acid and uses thereof
US10781175B2 (en) 2016-07-15 2020-09-22 Am Chemicals Llc Solid supports and phosphoramidite building blocks for oligonucleotide conjugates
KR101950881B1 (ko) * 2017-08-10 2019-02-22 서울대학교산학협력단 리포테이코익산(Lipoteichoic acid(LTA))을 함유하는 피부 재생 및 창상 치유용 약학 조성물
CA3074703A1 (en) * 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4714196A (en) * 1995-01-30 1996-08-21 Peter Truog Antitumor and anticholesterol preparations containing a lipoteichoic acid from steptococcus
AUPQ137699A0 (en) 1999-07-02 1999-07-22 University Of New England, The Control of acidosis
CA2474709A1 (en) * 2002-02-04 2003-08-14 Biomira, Inc. Immunostimulatory, covalently lipidated oligonucleotides

Also Published As

Publication number Publication date
EP2500349A1 (en) 2012-09-19
WO2012119846A1 (en) 2012-09-13
US20140050741A1 (en) 2014-02-20
HK1175786A1 (en) 2013-07-12
JP2014507450A (ja) 2014-03-27
EP2500349B1 (en) 2015-05-06
JP6154751B2 (ja) 2017-06-28
CA2829126A1 (en) 2012-09-13
US9290531B2 (en) 2016-03-22

Similar Documents

Publication Publication Date Title
ES2544808T3 (es) Miméticos sintéticos de LTA y uso de los mismos como componente de vacuna para la terapia y/o profilaxis de infecciones gram-positivas
MX393384B (es) Adyuvantes sinteticos de glucopiranosil-lipido.
AR076753A1 (es) Derivados de carboxamida y urea aromaticas sustituidas como ligandos del receptor de vanilloides.
CO6260103A2 (es) Composiciones que comprenden antigenos neumococidos
DOP2009000124A (es) Derivados de benzamida como receptores agonista ep4
Wahid et al. Live oral Salmonella enterica serovar Typhi vaccines Ty21a and CVD 909 induce opsonophagocytic functional antibodies in humans that cross-react with S. Paratyphi A and S. Paratyphi B
PA8827901A1 (es) Derivados de quinoxalin- y quinolin-carboxamida
RU2017123262A (ru) Иммуногенные композиции для применения в пневмококковых вакцинах
DOP2012000310A (es) Morfolinopirimidinas y su uso en terapia
CL2009002206A1 (es) Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
PA8815201A1 (es) Compuestos heterociclicos
NZ759686A (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
DOP2010000387A (es) Compuestos pirazolicos 436
BR112012013431A8 (pt) composto, composição farmacêutica e seu uso
Basset et al. Toll-like receptor (TLR) 2 mediates inflammatory responses to oligomerized RrgA pneumococcal pilus type 1 protein
AR078522A1 (es) Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
ECSP11011327A (es) Derivados de aminotetralina, composiciones farmacéuticas que los contienen, y sus usos en terapia
UY32062A (es) Inhibidores de beta-secretasa
CO6390101A2 (es) Compuestos purina
CR20120626A (es) Formulaciones farmacéuticas que comprenden derivados de 1-(beta- D-glucopiranosil)-2-tienilmetil]benceno como inhibidores de los transportadores de glucosa dependientes de sodio (SGLT)
MX2011012934A (es) Lipopolisacarido de ochrobactrum intermedium y su uso como inmunoestimulante en mamiferos.
AR069508A1 (es) Derivados de quinolina 057; un proceso para su preparacion; una composicion farmaceutica; la preparacion de esta y el uso del compuesto para preparar un medicamento
DOP2012000312A (es) Triazolopiridinas sustituidas
CU20120083A7 (es) Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificación para el uso como principio activo farmacéutico
BRPI0820258B8 (pt) composto, composições de vacina, e, uso de um composto